Compounds > 1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid, (s)-isomer
Page last updated: 2024-12-08

1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid, (s)-isomer

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## 1,2,3,4-Tetrahydro-β-carboline-3-carboxylic acid, (S)-isomer: An intriguing molecule

**1,2,3,4-Tetrahydro-β-carboline-3-carboxylic acid (THβC) is a heterocyclic compound with a complex structure, known to exist in two isomeric forms: (S)-THβC and (R)-THβC.** The (S)-isomer is the focus of this discussion.

**Importance in Research:**

(S)-THβC has attracted significant research interest for its potential roles in:

**1. Neurological and Psychiatric Disorders:**

* **Alzheimer's disease:** Studies suggest (S)-THβC might act as a neuroprotective agent against amyloid-β toxicity, a key player in Alzheimer's.
* **Parkinson's disease:** Some research points to its potential to protect dopaminergic neurons, which are vulnerable in Parkinson's disease.
* **Depression:** (S)-THβC might act as a selective serotonin reuptake inhibitor (SSRI), similar to common antidepressant medications.
* **Anxiety:** Preliminary evidence suggests potential anxiolytic effects of (S)-THβC.

**2. Chemical Biology and Medicinal Chemistry:**

* **Drug development:** Its unique structure and biological activity make (S)-THβC an interesting starting point for designing novel drugs.
* **Understanding biological processes:** Investigating (S)-THβC can contribute to a better understanding of the complex interplay between neurotransmitters and receptors.

**3. Food Chemistry and Toxicology:**

* **Food safety:** (S)-THβC is a byproduct of the Maillard reaction, a crucial process in food browning and flavor development.
* **Potential toxicity:** Understanding its formation and potential toxicity in foods is crucial for ensuring food safety.

**However, it's crucial to note that research on (S)-THβC is still in its early stages:**

* **Limited clinical data:** Most of the evidence comes from in vitro and animal studies. More research is needed to understand its efficacy and safety in humans.
* **Potential side effects:** Its precise mechanism of action and potential side effects are not fully understood.

**Overall, 1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid, (S)-isomer, holds promise as a potential therapeutic agent and a tool for understanding complex biological processes. However, extensive research is needed to translate its potential into real-world applications and ensure its safety for human use.**

lycoperodine-1: from Cirsium setosum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID449440
CHEMBL ID155546
SCHEMBL ID416557
MeSH IDM0323553

Synonyms (34)

Synonym
(s)-(-)-2,3,4,9-tetrahydro-1h-pyrido(3,4-b)indole-3-carboxylic
BIDD:GT0550
cyclomethyltryptophan
42438-90-4
l-1,2,3,4-tetrahydronorharman-3-carboxylic acid
CHEMBL155546
(3s)-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole-3-carboxylic acid
AKOS004907297
(3s)-1h,2h,3h,4h,9h-pyrido[3,4-b]indole-3-carboxylic acid
(s)-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole-3-carboxylic acid
A15567
AKOS015856022
SCHEMBL416557
l-1,2,3,4-tetrahydronorharmane-3-carboxylic acid
(3s)-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid
(3s)-1,2,3,4-tetrahydro-9h-pyrido[3,4-b]indole-3-carboxylic acid
FSNCEEGOMTYXKY-JTQLQIEISA-N
AC-25326
mfcd00272641
(-)-(3s)-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid
tnca, >=98% (hplc)
3s_2349_tetrahydro_1h_pyrido_34b_indole_carboxylic_acid
(3s)-2,3,4,9-tetrahydro-1h-beta-carboline-3-carboxylic acid
h-tpi-oh;l-1,2,3,4-tetrahydro--carboline-3-carboxylic acid;l-tryptoline-3-carboxylic acid;l-1,2,3,4-tetrahydro-9h-pyrido[3,4-b]indole-3-carboxylic acid
h-tpi-oh
Q27466042
PS-12531
DTXSID40962491
lycoperodine-1
(s)-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole-3-carboxylicacid
CS-0082781
EN300-312396
(s)-1,2,3,4-tetrahydronorharmane-3-carboxylic acid
Z1508915935
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID388927Inhibition of platelet-activating factor-induced platelet aggregation in pig blood2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
(3S)-N-(L-Aminoacyl)-1,2,3,4-tetrahydroisoquinolines, a class of novel antithrombotic agents: synthesis, bioassay, 3D QSAR, and ADME analysis.
AID473123Antiplatelet aggregation activity against arachidonic acid-induced pig platelet aggregation after 5 mins by aggregometer2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
A class of 3S-2-aminoacyltetrahydro-beta-carboline-3-carboxylic acids: their facile synthesis, inhibition for platelet activation, and high in vivo anti-thrombotic potency.
AID473125Antiplatelet aggregation activity against thrombin-induced pig platelet aggregation after 5 mins by aggregometer2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
A class of 3S-2-aminoacyltetrahydro-beta-carboline-3-carboxylic acids: their facile synthesis, inhibition for platelet activation, and high in vivo anti-thrombotic potency.
AID165509Tested in vitro for maximal rate of platelet aggregation induced by adenosine diphosphate (10 e5 mol/L) at a dose of 10 e6 mol/L in rabbit blood2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Synthesis and antithrombotic activity of carbolinecarboxyl RGD sequence.
AID630252Inhibition of TNF-alpha-induced NFkappaB activation in human HEK293 cells at 50 uM after 6 hrs by luciferase assay relative to control2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Design, synthesis, and biological evaluation of callophycin A and analogues as potential chemopreventive and anticancer agents.
AID190471Tested for the effect on the dry thrombus weight at a dose of 5 uM/kg in male wistar anesthetized rat2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Synthesis and antithrombotic activity of carbolinecarboxyl RGD sequence.
AID473131Antithrombotic activity in Wistar rat arterioveinos cannula model assessed as reduction of thrombus weight at 5 umol/kg, iv2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
A class of 3S-2-aminoacyltetrahydro-beta-carboline-3-carboxylic acids: their facile synthesis, inhibition for platelet activation, and high in vivo anti-thrombotic potency.
AID388925Inhibition of adenosine diphosphate-induced platelet aggregation in pig blood2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
(3S)-N-(L-Aminoacyl)-1,2,3,4-tetrahydroisoquinolines, a class of novel antithrombotic agents: synthesis, bioassay, 3D QSAR, and ADME analysis.
AID200412Tested for the effect of compound on the adhesion of high pulmonary metastatic SACC cell line SACC-LM and platelets at 5 mg/mL2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Synthesis and antithrombotic activity of carbolinecarboxyl RGD sequence.
AID388926Inhibition of arachidonic acid-induced platelet aggregation in pig blood2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
(3S)-N-(L-Aminoacyl)-1,2,3,4-tetrahydroisoquinolines, a class of novel antithrombotic agents: synthesis, bioassay, 3D QSAR, and ADME analysis.
AID630247Inhibition of aromatase at 50 uM after 10 mins preincubation by plate reader relative to control2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Design, synthesis, and biological evaluation of callophycin A and analogues as potential chemopreventive and anticancer agents.
AID165508Tested in vitro for maximal rate of platelet aggregation induced by adenosine diphosphate (10 e5 mol/L) at a dose of 10 e5 mol/L in rabbit blood2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Synthesis and antithrombotic activity of carbolinecarboxyl RGD sequence.
AID630244Induction of quinone reductase 1 activity in mouse Hepa-1c1c7 cells at 50 uM by MTT assay relative to untreated control2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Design, synthesis, and biological evaluation of callophycin A and analogues as potential chemopreventive and anticancer agents.
AID165512Tested in vitro for the maximal rate of platelet aggregation induced by platelet activating factor (10 e-7 mol/L) at a dose of 10 e6 mol/L in rabbit blood2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Synthesis and antithrombotic activity of carbolinecarboxyl RGD sequence.
AID388928Inhibition of thrombin-induced platelet aggregation in pig blood2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
(3S)-N-(L-Aminoacyl)-1,2,3,4-tetrahydroisoquinolines, a class of novel antithrombotic agents: synthesis, bioassay, 3D QSAR, and ADME analysis.
AID165513Tested in vitro for the maximal rate of platelet aggregation induced by platelet activating factor (10 e-7 mol/L) at a dose of 10 e7 mol/L in rabbit blood2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Synthesis and antithrombotic activity of carbolinecarboxyl RGD sequence.
AID165511Tested in vitro for the maximal rate of platelet aggregation induced by platelet activating factor (10 e-7 mol/L) at a dose of 10 e5 mol/L in rabbit blood2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Synthesis and antithrombotic activity of carbolinecarboxyl RGD sequence.
AID630249Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells at 50 uM pretreated 15 mins before LPS challenge measured after 20 hrs relative to control2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Design, synthesis, and biological evaluation of callophycin A and analogues as potential chemopreventive and anticancer agents.
AID165510Tested in vitro for maximal rate of platelet aggregation induced by adenosine diphosphate (10 e5 mol/L) at a dose of 10 e7 mol/L in rabbit blood2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Synthesis and antithrombotic activity of carbolinecarboxyl RGD sequence.
AID190475Tested for the effect on the wet thrombus weight at a dose of 5 umol/kg in male wistar anesthetized rat2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Synthesis and antithrombotic activity of carbolinecarboxyl RGD sequence.
AID630250Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells assessed as cell survival at 50 uM pretreated 15 mins before LPS challenge measured after 20 hrs relative to control2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Design, synthesis, and biological evaluation of callophycin A and analogues as potential chemopreventive and anticancer agents.
AID630253Inhibition of TNF-alpha-induced NFkappaB activation in human HEK293 cells assessed as cell survival at 50 uM after 6 hrs by luciferase assay relative to control2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Design, synthesis, and biological evaluation of callophycin A and analogues as potential chemopreventive and anticancer agents.
AID473122Antiplatelet aggregation activity against platelet-activating factor-induced pig platelet aggregation after 5 mins by aggregometer2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
A class of 3S-2-aminoacyltetrahydro-beta-carboline-3-carboxylic acids: their facile synthesis, inhibition for platelet activation, and high in vivo anti-thrombotic potency.
AID473124Antiplatelet aggregation activity against ADP-induced pig platelet aggregation after 5 mins by aggregometer2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
A class of 3S-2-aminoacyltetrahydro-beta-carboline-3-carboxylic acids: their facile synthesis, inhibition for platelet activation, and high in vivo anti-thrombotic potency.
AID1167629Antioxidant activity assessed as ratio of trolox equivalents of ABTS radical scavenging activity after 6 mins2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Design, synthesis and evaluation of novel tacrine-(β-carboline) hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID630245Induction of quinone reductase 1 activity in mouse Hepa-1c1c7 cells assessed as cell survival at 50 uM by MTT assay relative to control2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Design, synthesis, and biological evaluation of callophycin A and analogues as potential chemopreventive and anticancer agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.43 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
4'-bromoflavone
4'-bromoflavone: structure in first source		2.0610
tacrine
Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.. tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.		2.110acridines;
aromatic amine		EC 3.1.1.7 (acetylcholinesterase) inhibitor
aspirin
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.		2.4520benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		2.110aromatic ether;
nitrile;
polyether;
tertiary amino compound
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		2.110aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
clonidine
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.		2.110clonidine;
imidazoline
harmaline
Harmaline: A beta-carboline alkaloid isolated from seeds of PEGANUM.. harmaline : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7 and has been reduced across the 3,4 bond.		2.0510harmala alkaloidoneirogen
harmalol
harmalol: inhibitor of rat liver microsomal UDP-glucuronyltransferase; RN given refers to parent cpd; structure. harmalol : A harmala alkaloid in which the harman skeleton is hydroxy-substituted at C-7 and has been reduced across the 3,4 bond.		2.0510harmala alkaloidalgal metabolite;
EC 1.4.3.4 (monoamine oxidase) inhibitor
corticosterone
[no description available]		2.11011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
galantamine
Galantamine: A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.. galanthamine : A benzazepine alkaloid isolated from certain species of daffodils.		2.110benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound		antidote to curare poisoning;
cholinergic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant metabolite
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		2.0610delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
norharman
norharman: RN given refers to parent cpd. beta-carboline : The parent compound of the beta-carbolines, a tricyclic structure comprising an indole ring system ortho- fused to C-3 and C-4 of a pyridine ring.		2.0510beta-carbolines;
mancude organic heterotricyclic parent		fungal metabolite;
marine metabolite
harmol hydrochloride
[no description available]		2.0510
beta-carboline-3-carboxylic acid methyl ester
beta-carboline-3-carboxylic acid methyl ester: structure given in first source		2.110beta-carbolines
arginyl-glycyl-aspartyl-serine
arginyl-glycyl-aspartyl-serine: corresponds to cell attachment site of fibronectin; located near carboxyl-terminal region of alpha-chain of fibrinogen; inhibits platelet aggregation & fibrinogen binding to activated platelets		2.0110
omega-n-methylarginine
omega-N-Methylarginine: A competitive inhibitor of nitric oxide synthetase.. N(omega)-methyl-L-arginine : A L-arginine derivative with a N(omega)-methyl substituent.		2.0610amino acid zwitterion;
arginine derivative;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid
naringenin
(S)-naringenin : The (S)-enantiomer of naringenin.		2.0610(2S)-flavan-4-one;
naringenin		expectorant;
plant metabolite
tosylphenylalanyl chloromethyl ketone
Tosylphenylalanyl Chloromethyl Ketone: An inhibitor of Serine Endopeptidases. Acts as alkylating agent and is known to interfere with the translation process.. N-tosyl-L-phenylalanyl chloromethyl ketone : The N-tosyl derivative of L-phenylalanyl chloromethyl ketone.		2.0610alpha-chloroketone;
sulfonamide		alkylating agent;
serine proteinase inhibitor
glycosides
[no description available]		2.0510
quercetin
[no description available]		2.05107-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
harmine
Harmine: Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic PARKINSON DISEASE in the 1920's.. harmine : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7.		2.0510harmala alkaloidanti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
metabolite
harman
harman: a beta-carboline; RN given refers to parent cpd; structure. harman : An indole alkaloid fundamental parent with a structure of 9H-beta-carboline carrying a methyl substituent at C-1. It has been isolated from the bark of Sickingia rubra, Symplocus racemosa, Passiflora incarnata, Peganum harmala, Banisteriopsis caapi and Tribulus terrestris, as well as from tobacco smoke. It is a specific, reversible inhibitor of monoamine oxidase A.		2.0510harmala alkaloid;
indole alkaloid fundamental parent;
indole alkaloid		anti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
plant metabolite
piroxicam
[no description available]		2.110benzothiazine;
monocarboxylic acid amide;
pyridines		analgesic;
antirheumatic drug;
cyclooxygenase 1 inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
ConditionIndicatedRelationship StrengthStudiesTrials
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0110
Blood Clot
[description not available]		02.0110
Thrombosis
Formation and development of a thrombus or blood clot in the blood vessel.		02.0110
Breast Cancer
[description not available]		02.0610
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.0610
Acute Confusional Senile Dementia
[description not available]		02.110
Protein Aggregation, Pathological
A biochemical phenomenon in which misfolded proteins aggregate either intra- or extracellularly. Triggered by factors such as MUTATION; POST-TRANSLATIONAL MODIFICATIONS, and environmental stress, it is generally associated with ALZHEIMER DISEASE; PARKINSON DISEASE; HUNTINGTON DISEASE; and TYPE 2 DIABETES MELLITUS.		02.110
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		02.110